Description
Lurbinectedin is used in the treatment of metastatic small cell lung cancer and has shown efficacy in other solid tumors. It is not currently approved for use in colorectal cancer but is under investigation for potential applications in this setting.
Mechanism of Action
Lurbinectedin inhibits RNA polymerase II, which is essential for the transcription of genes involved in cell proliferation and survival.
Side Effects
Neutropenia; anemia; trombocitopenia; náuseas; vómitos; fatiga;
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02611024
med_phase_prefix1
Completed
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
United States, France, Germany, Italy, Spain, Switzerland